Belltree Consulting Team
Teri Suzuki
​
Dr. Suzuki has more than 20 years of industrial R&D experience in biological sciences. She began her career with Selectide (later Sanofi) as a laboratory scientist. At Sanofi she became a project manager for major pharmaceutical lead discovery projects. She initiated and led multi-year collaborations with academic laboratories which centered on novel drug targets. She also initiated collaborations with biotech companies developing novel eADMET instrumentation. She holds undergraduate degrees in chemistry and biochemistry and a Ph.D. in Biochemistry (University of Arizona). She is an Angel Investor with Tucson's Desert Angels and serves on the External Advocacy Board for the University of Arizona's Mathematics Department and the External Advisory Board for the University of Arizona's Undergraduate Biology Research Program. Current consulting clients include Reglagene and the University of Arizona Health Sciences Asthma and Airway Disease Research Center.
Mark Chapman
​
Dr. Chapman is a veteran of large and small biotech companies. He is well versed in all aspects of drug discovery, from target selection, validation, screening, hit-to-lead, lead optimization, preclinical testing, candidate selection, and early clinical development. He has worked with small molecules as well as therapeutic antibodies. Mark has led cross functional teams, established partnerships with CROs, clinicians, and academic groups, and is adept at addressing key questions in a cost effective manner. He has deep knowledge in oncology, and has additional experience in endocrinology and immunology. He holds a BA in genetics (UC Berkeley), a PhD in Biochemistry (University of Arizona), and trained at the Salk Institute. Consulting clients include Celgene, Aragon Pharmaceuticals, Reglagene, Hillhurst Biopharmaceuticals, Sanofi Aventis, and Molecular Response.
Paul Wright
​
Dr. Wright has over 30 years of industry experience in drug discovery at Hoechst, Aventis and Sanofi, including serving as the Section Head of Cell Biology and Section Head of Molecular Pharmacology. At Hoechst he also served as the Preclinical Oncology Product Expert for the HMR 1275 (Flavopiridol) Clinical Development Project Team. His areas of expertise include Oncology (Breast, Prostate, Lung, and Colon Cancer), Inflammation (Asthma), Vascular cell biology (angiogenesis). Dr. Wright has extensive experience leading teams in Target Identification and Validation Technologies (Transcript profiling, RT-PCR, in situ analysis of gene expression, RNAi). He has 9 patents and 36 publications in areas directly related to drug discovery and mechanisms of human disease. He received a B.S. in Chemistry (Boise State University) and a Ph.D. in Biochemistry (Purdue University), with post-doctoral training from University of Iowa and U.C. Davis.